جهانی در حال گسترش از مواد روان گردان جدید – بنزودیازپین های طراحی شده (DBZD)

نوع مقاله: مقاله پژوهشی

نویسندگان

1 کارشناس بیوشیمی

2 کارشناس انتظامی

چکیده

  سوء استفاده از مواد روان گردان جدید (NPS) از اواخر دهه 2000 در سرتاسر جهان به طور چشمگیری افزایش یافته است . بین سال های 2009 تا 2017 در مجموع 803 نوع NPS ویژه توسط 111 کشور و حوزه به دفتر مواد مخدر و جرم سازمان ملل گزارش شده است. اگرچه عمومی ترین این ترکیبات کانابینوئید های مصنوعی و مشتقات کاتیون های محرک (به اصطلاح بتا کتوآمفتامین ها) هستند، بنزودیازپین های جدید به تازگی در بازار داروهای تفریحی ظاهر شده اند. سوء استفاده از "بنزودیازپین های طراحی شده" (DBZD) (یک نام مشترک برای کلاس NPS بنزودیازپین ها) در بسیاری از کشورها به یک معضل فزاینده ای تبدیل شده است.
گروه DBZD شامل نامزدهایی از داروهایی هستند که هرگز برای استفاده پزشکی تایید نشده اند.DBZD درواقع ترکیباتی هستند که با دستکاری و اصلاح ساختاری ساده یک دارو و نیز برخی متابولیت های فعال بنزودیازپین هایی سنتز شده اند. این مقاله اعضای گروه DBZD حال حاضر را بررسی می کند، و روند اپیدمیولوژیک و اثرات بالینی مرتبط با مصرف آن ها را شرح می دهد و داده های به دست آمده در خصوص متابولیسم آن ها را مورد بحث قرار می دهد و تاکید ویژه ای به موارد مسمومیت به این ترکیبات دارد.

کلیدواژه‌ها


El Balkhi, S., Chaslot, M., Picard, N., Dulaurent, S., Delage, M., Mathieu, O., Saint-

Marcoux, F., 2017. Characterization and identification of eight designer benzodiazepine

metabolites by incubation with human liver microsomes and analysis by a

triple quadrupole mass spectrometer. Int. J. Legal Med. 131 (4), 979–988. https://

doi.org/10.1007/s00414-017-1541-6.

EMCDDA, 2016. European Drug Report. Trends and Developments. Accessed 29

November 2018. http://www.emcdda.europa.eu/system/files/publications/2637/

TDAT16001ENN.pdf.

EMCDDA, 2018a. Perspective on Drugs. The Misuse of Benzodiazepines Among High-risk

Opioid Users in Europe. Accessed October 9, 2018. http://www.emcdda.europa.eu/

system/files/publications/2733/Misuse%20of%20benzos_POD2015.pdf.

EMCDDA, 2018b. European Drug Report. Trends and Developments, 2018. Accessed

October 9, 2018. http://www.emcdda.europa.eu/system/files/publications/8585/

20181816_TDAT18001ENN_PDF.pdf.

Ghazi, M.A., Mohmand, M., 2017. Co-occurring addition of synthetic benzodiazepine

clonazolam and propylhexedrine presenting as acute brief psychosis. J. Addict. Med.

Ther. Sci. 5 (2), 1037.

Gjerde, H., Christophersen, A.S., Normann, P.T., Mørland, J., 2011. Toxicological investigations

of drivers killed in road traffic accidents in Norway during 2006-2008.

Forensic Sci. Int. 212 (1–3), 102–109. https://doi.org/10.1016/j.forsciint.2011.05.

021.

Griffin 3rd, C.E., Kaye, A.M., Bueno, F.R., Kaye, A.D., 2013. Benzodiazepine pharmacology

and central nervous system-mediated effects. Ochsner J. 13 (2), 214–223.

Gupta, S., Garg, B., 2014. A case of etizolam dependence. Indian J. Pharmacol. 46 (6),

655–656. https://doi.org/10.4103/0253-7613.144943.

Høiseth, G., Tuv, S.S., Karinen, R., 2016. Blood concentrations of new designer benzodiazepines

in forensic cases. Forensic Sci. Int. 268, 35–38. https://doi.org/10.1016/j.

forsciint.2016.09.006.

Huppertz, L.M., Moosmann, B., Auwärter, V., 2018. Flubromazolam - Basic pharmacokinetic

evaluation of a highly potent designer benzodiazepine. Drug Test. Anal. 10

(1), 206–211. https://doi.org/10.1002/dta.2203.

Jones, J.D., Mogali, S., Comer, S.D., 2012. Polydrug abuse: a review of opioid and benzodiazepine

combination use. Drug Alcohol Depend. 125 (1–2), 8–18. https://doi.

org/10.1016/j.drugalcdep. 2012.07.004.

Karinen, R., Tuv, S.S., Rogde, S., Peres, M.D., Johansen, U., Frost, J., Vindenes, V.,

Øiestad, Å.M., 2014. Lethal poisonings with AH-7921 in combination with other

substances. Forensic Sci. Int. 244, e21–24. https://doi.org/10.1016/j.forsciint.2014.

08.013.

Katselou, M., Papoutsis, I., Nikolaou, P., Spiliopoulou, C., Athanaselis, S., 2017.

Metabolites replace the parent drug in the drug arena. The cases of fonazepam and

nifoxipam. Forensic Toxicol. 35 (1), 1–10. https://doi.org/10.1007/s11419-016-

0338-5.

Kerrigan, S., Mellon, M.B., Hinners, P., 2013. Detection of phenazepam in impaired

driving. J. Anal. Toxicol. 37 (8), 605–610. https://doi.org/10.1093/jat/bkt075.

Kintz, P., Richeval, C., Jamey, C., Ameline, A., Allorge, D., Gaulier, J.M., Raul, J.S.,

2017a. Detection of the designer benzodiazepine metizolam in urine and preliminary

data on its metabolism. Drug Test. Anal. 9 (7), 1026–1033. https://doi.org/10.1002/

dta.2099.

Kintz, P., Jamey, C., Ameline, A., Richeval, C., Raul, J.S., 2017b. Characterization of

metizolam, a designer benzodiazepine, in alternative biological specimens. Toxicol.

Anal. Clin. 29, 57–63 https://dx.doi.org/1016/j.toxac.2016.09.04.

Koch, K., Auwärter, V., Hermanns‐Clausen, M., Wilde, M., Neukamm, M.A., 2018. Mixed

intoxication by the synthetic opioid U‐47700 and the benzodiazepine flubromazepam

with lethal outcome: pharmacokinetic data. Drug Test. Anal https://doi.org/

10.1002/dta.2391.

Kriikku, P., Wilhelm, L., Rintatalo, J., Hurme, J., Kramer, J., Ojanperä, I., 2012.

Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases

and police confiscations. Forensic Sci. Int. 220 (1–3), 111–117. https://doi.org/10.

1016/j.forsciint.2012.02.006.

Liveri, K., Constantinou, M.A., Afxentiou, M., Kanari, P., 2016. A fatal intoxication related

to MDPV and pentedrone combined with antipsychotic and antidepressant substances

in Cyprus. Forensic Sci. Int. 265, 160–165. https://doi.org/10.1016/j.forsciint.2016.

02.017.

Lomas, E.C., Maskell, P.D., 2015. Phenazepam: more information coming in from the

cold. J. Forensic Leg. Med. 36, 61–62. https://doi.org/10.1016/j.jflm.2015.08.017.

Łukasik-Głębocka, M., Sommerfeld, K., Teżyk, A., Zielińska-Psuja, B., Panieński,

immunochemical

screening assays. Drug Test. Anal. 9 (4), 640–645. https://doi.org/10.

1002/dta.2003.

Pettersson Bergstrand, M., Meyer, M.R., Beck, O., Helander, A., 2018. Human urinary

metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam

studied by liquid chromatography-high resolution mass spectrometry. Drug Test.

Anal. 10 (3), 496–506. https://doi.org/10.1002/dta.2243.

Pettersson Bergstrand, M., Richter, L.H.J., Maurer, H.H., Wagmann, L., Meyer, M.R.,

2019. In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases.

Drug Test. Anal. 11 (1), 45–50. https://doi.org/10.1002/dta.2463.

Pope, J.D., Choy, K.W., Drummer, O.H., Schneider, H.G., 2018. Novel benzodiazepines

(clonazolam and flubromazolam) identified in candy-like pills. J. Appl. Lab. Med. 3

(1), 48–55. https://doi.org/10.1373/jalm.2017.025387.

Shearer, K., Bryce, C., Parsons, M., Torrance, H., 2015. Phenazepam: a review of medicolegal

deaths in South Scotland between 2010 and 2014. Forensic Sci. Int. 254,

197–204. https://doi.org/10.1016/j.forsciint.2015.07.033.

Stephenson, J.B., Golz, D.E., Brasher, M.J., 2013. Phenazepam and its effects on driving.

J. Anal. Toxicol. 37 (1), 25–29. https://doi.org/10.1093/jat/bks080.

Švidrnoch, M., Boráňová, B., Tomková, J., Ondra, P., Maier, V., 2018. Simultaneous determination

of designer benzodiazepines in human serum using non-aqueous capillary

electrophoresis - Tandem mass spectrometry with successive multiple ionic -

Polymer layer coated capillary. Talanta 176, 69–76 https://doi.org/ 10.1016/j.talanta.

2017.08.010.

Tan, K.R., Rudolph, U., Lüscher, C., 2011. Hooked on benzodiazepines: GABAA receptor

subtypes and addiction. Trends Neurosci. 34 (4), 188–197 https://doi.org/ 10.1016/

j.tins.2011.01.004.

Tanaka, N., Kinoshita, H., Nishiguchi, M., Jamal, M., Kumihashi, M., Takahashi, M.,

Nishio, H., Ameno, K., 2011a. An autopsy case of multiple psychotropic drug poisoning.

Soud. Lek. 56 (3), 38–39.

Tanaka, N., Kinoshita, H., Jamal, M., Ohkubo, E., Kumihashi, M., Ameno, K., 2011b. A

case of drowning whilst under the influence of brotizolam, flunitrazepam and

ethanol. Soud. Lek. 56 (1), 5–6.

TripSit FactSheets, http://drugs.tripsit.me. Accessed 11 October 2018.

UNODC, 2017a. Non-medical Use of Benzodiazepines: a Growing Threat to Public

Health? Global Smart Update. pp. 18. https://www.unodc.org/documents/scientific/

Global_SMART_Update_2017_Vol_18.pdf.

UNODC, 2017b. The Challenge of Synthetic Drugs in East and South-East Asia. Trends and

Patterns of Amphetamine-type Stimulants and New Psychoactive Substances.

Accessed 9 October 2018.. https://www.unodc.org/documents/scientific/Trends_

and_Patterns_of_ATS_and_NPS_2017.pdf.

UNODC, 2017c. April 2017 – UNODC: Several Countries Place Benzodiazepine

Derivatives Under National Control. Accessed 9 October 2018.. https://www.unodc.

org/LSS/Announcement/Details/065118d5-b238-48d8-9d7f-b95fb5d11411.

UNODC, 2018. June 2018 – Scotland: Number of Deaths Involving Benzodiazepine-type

NPS Etizolam and Diclazepam Increase Sharply in 2016. Accessed October 9, 2018.

https://www.unodc.org/LSS/Announcement/Details/0ec8745d-da7e-4594-a47fc47005a8ae96.

US Department of Justice Drug Enforcement Administration, 2009. Blotter acid mimic

(actually containing phenazepam) in North Carolina. Microgram Bulletin 42, 94.

Valen, A., Bogstrand, S.T., Vindenes, V., Gjerde, H., 2017. Toxicological findings in suspected

drug-impaired drivers in Norway - Trends during 1990-2015. Forensic Sci. Int.

280, 15–24. https://doi.org/10.1016/j.forsciint.2017.09.010.

Vikingsson, S., Wohlfarth, A., Andersson, M., Gréen, H., Roman, M., Josefsson, M.,

Kugelberg, F.C., Kronstrand, R., 2017. Identifying metabolites of meclonazepam by

high-resolution mass spectrometry using human liver microsomes, hepatocytes, a

mouse model, and authentic urine samples. AAPS J. 19 (3), 736–742. https://doi.

org/10.1208/s12248-016-0040-x.

Wakakura, M., Tsubouchi, T., Inouye, J., 2004. Etizolam and benzodiazepine induced

blepharospasm. J. Neurol. Neurosurg. Psychiatry. 75 (3), 506–507.

WHO, 2015. Phenazepam. Pre-review Report. Agenda Item 5.8. Expert Committee on

Drug Dependence Thirty-seventh Meeting. Geneva, 16-20 November 2015. . http://

www.who.int/medicines/access/controlled-substances/5.8_Phenazepam_PreRev.pdf.

WHO, 2017. ETIZOLAM Critical Review Report. Agenda Item 4.13. Expert Committee on

Drug DependenceThirty-ninth Meeting Geneva, 6-10 November. 2017. http://www.

who.int/medicines/access/controlled-substances/CriticalReview_Etizolam.pdf.

Wohlfarth, A., Vikingsson, S., Roman, M., Andersson, M., Kugelberg, F.C., Green, H.,

Kronstrand, R., 2017. Looking at flubromazolam metabolism from four different

angles: metabolite profiling in human liver microsomes, human hepatocytes, mice

and authentic human urine samples with liquid chromatography high-resolution

 

Abouchedid, R., Gilks, T., Dargan, P.I., Archer, J.R.H., Wood, D.M., 2018. Assessment of

the availability, cost, and motivations for use over time of the new psychoactive

substances – benzodiazepines diclazepam, flubromazepam, and pyrazolam – in the

UK. J. Med. Toxicol. 14 (2), 134–143. https://doi.org/10.1007/s13181-018-0659-3.

Advice Council on Misuse of Drugs, 2017. Circular 008/2017: a Change to the Misuse of

Drugs Act 1971 to Control U-47,700, Twelve Methylphenidate Related Substances

and Sixteen ‘designer’ Benzodiazepines. Accessed 29 November 2018. https://assets.

publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/

file/616781/misuse_of_drugs_act_circular_008_2017.pdf.

Advisory Council on the Misuse of Drugs, 2011. Phenazepam Advice. Available from:

http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/acmdadvice-

phenazepam?view=Binary. Accessed October 12, 2018.

Ali, A., Jerry, J.M., Khawam, E.A., 2015. Delirium induced by a new synthetic legal intoxicating

drug: phenazepam. Psychosomatics 56 (4), 414–418. https://doi.org/10.

1016/j.psym.2014.05.018.

Ameline, A., Richeval, C., Gaulier, J.-M., Raul, J.-S., Kintz, P., 2018. Detection of the

designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism.

Drug Test. Anal. https://doi.org/10.1002/dta.2480.

Anderson, M., Kjeligren, A., 2017. The slippery slope of flubromazolam: experiences of a

novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nordic

Studies Alc. Drugs 34 (3), 217–229. https://doi.org/10.1177/1455072517706304.

Arens, A.M., van Wijk, X.M., Vo, K.T., Lynch, K.L., Wu, A.H., Smollin, C.G., 2016. Adverse

effects from counterfeit alprazolam tablets. JAMA Intern. Med. 176 (10), 1554–1555.

https://doi.org/10.1001/jamainternmed.2016.4306.

Bäckberg, M., Pettersson Bergstrand, M., Beck, O., Helander, A., 2018. Occurrence and

time course of NPS benzodiazepines in Sweden - results from intoxication cases in the

STRIDA project. Clin. Toxicol. Phila. (Phila) https://doi.org/ 10.1080/

15563650.2018.1506130.

Bailey, K., Richards-Waugh, L., Clay, D., Gebhardt, M., Mahmoud, H., Kraner, J.C., 2010.

Fatality involving the ingestion of phenazepam and poppy seed tea. J. Anal. Toxicol.

34 (8), 527–532.

Benerjee, D., 2018. Etizolam withdrawal catatonia: the first case report. Asian J.

Psychiatr. 37, 32–33. https://doi.org/10.1016/j.ajp.2018.07.019.

Benesch, M.G.K., Iqbal, S.J., 2018. Novel psychoactive substances: overdose of 3-fluorophenmetrazine

(3-FPM) and etizolam in a 33-year-old man. BMJ Case Rep.

2018https://doi.org/10.1136/bcr-2018-224995. pii: bcr-2018-224995.

Bertol, E., Di Milia, M.G., Fioravanti, A., Mari, F., Palumbo, D., Pascali, J.P., Vaiano, F.,

2018. Proactive drugs in DFSA cases: toxicological findings in an eight-years study.

Forensic Sci. Int. 291, 207–215. https://doi.org/10.1016/j.forsciint.2018.08.032.

Carpenter, J.E., Murray, B.P., Dunkley, C., Kazzi, Z.N., Gittinger, M.H., 2018. Designer

benzodiazepines: a report of exposures recorded in the National Poison Data System,

2014–2017. Clin. Toxicol. Phila. (Phila). https://doi.org/10.1080/15563650.2018.

1510502.

Corkery, J.M., Schifano, F., Ghodse, A.H., 2012. Phenazepam abuse in the UK: an

emerging problem causing serious adverse health problems, including death. Hum.

Psychopharmacol. 27 (3), 254–261. https://doi.org/10.1002/hup.2222.

Couch, R.A., Madhavaram, H., 2012. Phenazepam and cannabinomimetics sold as herbal

highs in New Zealand. Drug Test. Anal. 4 (6), 409–414.

Crichton, M.L., Shenton, C.F., Drummond, G., Beer, L.J., Seetohul, L.N., Maskell, P.D.,

2015. Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and

tissues. Drug Test. Anal. 7 (10), 926–936. https://doi.org/10.1002/dta.1790.

Dargan, P.I., Davies, S., Puchnarewicz, M., Johnston, A., Wood, D.M., 2013. First reported

case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically

confirmed recreational use of phenazepam. Eur. J. Clin. Pharmacol. 69 (3),

361–363. https://doi.org/10.1007/s00228-012-1361-z.

Domingo, O., Roider, G., Stöver, A., Graw, M., Musshoff, F., Sachs, H., Bicker, W., 2017.

Mitragynine concentrations in two fatalities. Forensic Sci. Int. 271, e1–e7. https://

doi.org/10.1016/j.forsciint. 2016.12.020.

Drummer, O.H., Kourtis, I., Beyer, J., Tayler, P., Boorman, M., Gerostamoulos, D., 2012.

The prevalence of drugs in injured drivers. Forensic Sci. Int. 215 (1–3), 14–17.

https://doi.org/10.1016/j.forsciint.2011.01.040.

P., Żaba,

C., 2016. Flubromazolam – A new life-threatening designer benzodiazepine. Clin.

Toxicol. Phila. (Phila) 54 (1), 66–68. https://doi.org/10.3109/15563650.2015.

1112907.

Manchester, K.R., Lomas, E.C., Waters, L., Dempsey, F.C., Maskell, P.D., 2018. The

emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug

Test. Anal. 10 (2), 392–393. https://doi.org/10.1002/dta.2349.

Maskell, P.D., Paoli, G.D., Seetohul, L.N., Pounder, D.J., 2011. Phenazepam is currently

being misused in the UK. BMJ 343, d4207. https://doi.org/10.1136/bmj.d4207.

Meng, L., Zhu, B., Zheng, K., Fu, S., 2017. Ultrasound-assisted low-density solvent dispersive

liquid-liquid microextraction for the determination of 4 designer benzodiazepines

in urine samples by gas chromatography-triple quadrupole mass spectrometry.

J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1053, 9–15. https://doi.

org/10.1016/j.jchromb.2017.04.008.

Meyer, M.R., Pettersson Bergstrand, M., Helander, A., Beck, O., 2016. Identification of

main human urinary metabolites of the designer nitrobenzodiazepines clonazolam,

meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass

spectrometry for drug testing purposes. Anal. Bioanal. Chem. 408 (13), 3571–3591.

https://doi.org/10.1007/s00216-016-9439-6.

Ministry of Justice, Canada, 2018. Benzodiazepines and Other Targeted Substances

Regulations. Accessed January 3, 2019. https://laws-lois.justice.gc.ca/PDF/SOR-

2000-217.pdf.

Moosmann, B., Auwäter, V., 2018. Designer benzodiazepines: another class of new psychoactive

substances. Handb. Exp. Pharmacol. https://doi.org/10.1007/164_2018_

154.

Moosmann, B., Huppertz, L.M., Hutter, M., Buchwald, A., Ferlaino, S., Auwärter, V.,

2013. Detection and identification of the designer benzodiazepine flubromazepam

and preliminary data on its metabolism and pharmacokinetics. J. Mass Spectrom. 48

(11), 1150–1159. https://doi.org/10.1002/jms.3279.

Moosmann, B., Bisel, P., Auwärter, V., 2014. Characterization of the designer benzodiazepine

diclazepam and preliminary data on its metabolism and pharmacokinetics.

Drug Test. Anal. 6 (7–8), 757–763. https://doi.org/10.1002/dta.1628.

Moosmann, B., Bisel, P., Franz, F., Huppertz, L.M., Auwärter, V., 2016. Characterization

and in vitro phase I microsomal metabolism of designer benzodiazepines - an update

comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam

and nitrazolam. J. Mass Spectrom. 51 (11), 1080–1089. https://doi.org/10.

1002/jms.3840.

Moosmann, B., Bisel, P., Westphal, F., Wilde, M., Kempf, J., Angerer, V., Auwärter, V.,

2018. Characterization and in vitro phase I microsomal metabolism of designer

benzodiazepines - an update comprising flunitrazolam, norflurazepam and 4’-chlorodiazepam

(Ro5-4864). Drug Test. Anal https://doi.org. 10.1002/dta.2561.

Mortelé, O., Vervliet, P., Gys, C., Degreef, M., Cuykx, M., Maudens, K., Covaci, A., van

Nuijs, A.L.N., Lai, F.Y., 2018. In vitro Phase I and Phase II metabolism of the new

designer benzodiazepine cloniprazepam using liquid chromatography coupled to

quadrupole time-of-flight mass spectrometry. J. Pharm. Biomed. Anal. 153, 158–167.

https://doi.org/10.1016/j.jpba.2018.02.032.

Noble, C., Mardal, M., Bjerre Holm, N., Stybe Johansen, S., Linnet, K., 2017. In vitro

studies on flubromazolam metabolism and detection of its metabolites in authentic

forensic samples. Drug Test. Anal. 9 (8), 1182–1191 https://doi.org/ 10.1002/

dta.2146.

O’Connell, C.W., Sadler, C.A., Tolia, V.M., Ly, B.T., Saitman, A.M., Fitzgerald, R.L., 2015.

Overdose of etizolam: the abuse and rise of a benzodiazepine analog. Ann. Emerg.

Med. 65 (4), 465–466. https://doi.org/10.1016/j.annemergmed.2014.12.019.

Papsun, D., Krywanczyk, A., Vose, J.C., Bundock, E.A., Logan, B.K., 2016. Analysis of MT-

45, a novel synthetic opioid, in human whole blood by LC-MS-MS and its identification

in a drug-related death. J. Anal. Toxicol. 40 (4), 313–317. https://doi.org/10.

1093/jat/bkw012.

Partridge, E., Trobbiani, S., Stockham, P., Charlwood, C., Kostakis, C., 2018. A case study

involving U-47700, diclazepam and flubromazepam–application of retrospective

analysis of HRMS data. J. Anal. Toxicol. 42 (9), 655–660. https://doi.org/10.1093/

jat/bky039.

Pettersson Bergstrand, M., Helander, A., Beck, O., 2016. Development and application of

a multi-component LC-MS/MS method for determination of designer benzodiazepines

in urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1035, 104–110. https://

doi.org/10.1016/j.jchromb.2016.08.047.

Pettersson Bergstrand, M., Helander, A., Hansson, T., Beck, O., 2017. Detectability of

designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II

mass spectrometry. Forensic Sci. Int. 274, 55–63. https://doi.org/10.1016/j.forsciint.

2016.10.021.

Xiang, P., Shen, M., Drummer, O.H., 2015. Review: drug concentrations in hair and their

relevance in drug facilitated crimes. J. Forensic Leg. Med. 36, 126–135. https://doi.

org/10.1016/j.jflm.2015.09.009.